BTIG raised the firm’s price target on Abbott to $135 from $128 and keeps a Buy rating on the shares as part of a broader research note on Medical Technology. The sector has seen a strong resurgence in recent weeks, and the recovery is warranted following months of panicked selling related to GLP-1 fears, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott Increases Quarterly Dividend for 52nd Consecutive Year
- Abbott boosts quarterly dividend 8% to 55c per share
- MDT, ABT: 2 Healthcare Dividend Aristocrat Stocks Hedge Funds are Bullish On
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Needham medtech analysts hold analyst/industry conference call